METASTATIC NON-SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test drug combo to outsmart lung Cancer's return
Disease control Recruiting nowThis study is for people with a specific type of advanced lung cancer (EGFR-mutant). It tests if adding standard chemotherapy to the usual targeted drug (osimertinib) works better than the drug alone. The goal is to see if the combination can keep the cancer from growing or sprea…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 17:10 UTC
-
New Two-Drug attack on Tough-to-Treat cancers begins human testing
Disease control Recruiting nowThis early-stage trial is testing the safety and initial effectiveness of a new oral drug, STC-15, when given alongside an existing immunotherapy called toripalimab. It will enroll about 188 adults with specific advanced cancers—including lung, melanoma, endometrial, and head/nec…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Portable electric device tested in global fight against spreading lung cancer
Disease control Recruiting nowThis study is testing whether adding a portable device that creates electric fields to standard drug treatments helps people with advanced lung cancer that has spread. About 734 participants will be randomly assigned to receive either the standard drugs alone or the drugs plus th…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Global race for better lung cancer treatment targets rare mutations
Disease control Recruiting nowThis global Phase 3 trial is comparing a new drug called firmonertinib against two existing standard treatments for people with advanced non-small cell lung cancer that has specific, less common EGFR genetic mutations. The study aims to see if firmonertinib can better control the…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New 'Living Drug' trial aims to fight advanced cancers that resist other treatments
Disease control Recruiting nowThis study is testing a new type of personalized cell therapy called OBX-115 in adults with advanced melanoma or non-small cell lung cancer that has progressed after standard treatments. Doctors take a patient's own immune cells from a tumor, genetically engineer them to be more …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Obsidian Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for lung cancer patients when standard drug fails
Disease control Recruiting nowThis study is for people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) whose disease has gotten worse while taking the drug osimertinib. It will test whether a new drug called Dato-DXd, given alone or together with osimertinib, works better and is safer than s…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for Tough-to-Treat lung cancer: first patients test novel drug
Disease control Recruiting nowThis is the first study in people to test a new drug called BBO-8520 for advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to find a safe dose and see if the drug can help shrink tumors. The study will test BBO-8520 alone …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for lung cancer patients: major trial tests powerful drug combo
Disease control Recruiting nowThis study is testing whether adding a new drug called Dato-DXd to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for advanced lung cancer. It will involve 740 adults with a specific type of advanced non-small cell lung cancer who haven't had any p…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Cancer trial tests 'Less is More' approach to powerful drug
Disease control Recruiting nowThis study is testing a new method for giving the cancer drug atezolizumab. Researchers want to see if they can use lower doses, given less often, by carefully monitoring drug levels in a patient's blood. The goal is to see if this personalized approach can still control the canc…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Radiation blitz tested to halt spread of advanced lung cancer
Disease control Recruiting nowThis study is for people with advanced non-small cell lung cancer that has spread to only a few other body sites (1-5 spots). It compares the current standard maintenance drug therapy alone against that same drug therapy plus targeted, high-dose radiation to all the cancer spots.…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
Fighting lung cancer with a Patient's own supercharged immune cells
Disease control Recruiting nowThis study is testing a personalized treatment called LN-145 for people with metastatic non-small cell lung cancer that has worsened after standard therapy. Doctors take immune cells from a patient's own tumor, grow large numbers of them in a lab, and then infuse them back into t…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Major trial tests new weapon against advanced lung cancer
Disease control Recruiting nowThis study is testing whether a new drug called PF-08634404, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab with chemotherapy) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Doctors test Direct-to-Chest immune cell therapy for tough lung cancers
Disease control Recruiting nowThis is an early safety study testing a new type of personalized immune cell therapy for people with advanced non-small cell lung cancer that has spread to the lining of the chest. Doctors will collect a patient's own immune cells, modify them in a lab to target a specific protei…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Gentler treatment tested for frail lung cancer patients
Disease control Recruiting nowThis study is testing whether a lower dose of chemotherapy, when combined with immunotherapy, is safer and easier to tolerate for older or frail adults with advanced lung cancer. The main goal is to see if this gentler approach causes fewer severe side effects that would force pa…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
New Two-Drug attack on Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing whether a new drug called adagrasib works better alone or combined with an existing immunotherapy (pembrolizumab) for advanced lung cancer that has a specific genetic mutation called KRAS G12C. It will involve about 806 people who have not yet received treat…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC